Niemann-Pick Disease (NPD) Market Report 2026

The niemann-pick disease (npd) market size has grown rapidly in recent years. It will grow from $1.07 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to limited treatment availability, low disease awareness, delayed diagnosis rates, dependence on symptomatic management, high treatment costs.

The niemann-pick disease (npd) market size is expected to see rapid growth in the next few years. It will grow to $1.79 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to increasing rare disease funding, growth in gene therapy research, expanding newborn screening programs, rising healthcare expenditure, supportive regulatory incentives. Major trends in the forecast period include rising focus on early genetic screening, expansion of orphan drug development, increasing patient advocacy and awareness programs, growth in enzyme replacement and substrate reduction therapies, improved multidisciplinary disease management approaches.

The growing adoption of gene therapy is expected to drive the growth of the Niemann-Pick disease (NPD) market in the coming years. Gene therapy is a medical approach that involves modifying or manipulating an individual’s genes to treat or prevent disease. Its adoption is increasing due to advances in genetic engineering, which enable precise and effective gene modifications that enhance treatment outcomes for genetic disorders. In the context of Niemann-Pick disease, gene therapy targets the underlying genetic mutations, aiming to correct enzyme deficiencies that cause the disorder and improve cellular function. For example, in January 2024, according to the American Society of Gene and Cell Therapy, a U.S.-based organization for gene and cell therapy, the number of gene therapies in Phase III trials rose by 10% in the fourth quarter of 2023 compared to the previous quarter, marking the first increase since the third quarter of 2022. Therefore, the increasing adoption of gene therapy is contributing to the expansion of the Niemann-Pick disease market.

Major companies operating in the Niemann-Pick disease (NPD) market are concentrating on the development of advanced treatments, such as combination therapy, to improve treatment efficacy and patient outcomes. Combination therapy involves administering two or more therapeutic agents or treatment strategies to address a disease, aiming to enhance effectiveness and reduce the likelihood of resistance associated with single-agent therapy (monotherapy). For instance, in September 2024, Zevra Therapeutics Inc., a U.S.-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for MIPLYFFA in combination with miglustat for treating neurological manifestations of Niemann-Pick disease type C (NPC) in both adult and pediatric patients aged 2 years and older. MIPLYFFA (arimoclomol) works by boosting the production of heat shock proteins (HSPs), which help clear toxic lipid accumulation and protect neurons from damage, while miglustat inhibits glucosylceramide synthase to reduce lipid buildup. Together, these therapies help slow the progression of neurological decline in NPC patients.

In September 2024, Zevra Therapeutics, a U.S.-based biopharmaceutical company, partnered with Orsini to act as the exclusive specialty pharmacy provider for its newly approved Niemann-Pick disease type C therapy. Through this partnership, Zevra aims to ensure widespread patient access to MIPLYFFA (arimoclomol), the first FDA-approved treatment for NPC, by utilizing Orsini’s specialty pharmacy network for distribution and patient support. Orsini is a U.S.-based company that provides specialty pharmacy services for rare and complex diseases.

Major companies operating in the niemann-pick disease (npd) market are Sanofi S.A., Mayo Clinic, Cincinnati Children's Hospital Medical Center, Boston Children's Hospital, Mallinckrodt Pharmaceuticals plc, Myriad Genetics, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders (NORD), Evox Therapeutics Limited, Bloomsbury Genetic Therapies Ltd., Cyclo Therapeutics Inc., CarelonRx, Rainbow Children's Hospital, Vtesse Inc., Orphazyme A/S, Zebra Biologics, Sarepta Therapeutics Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Ultragenyx Pharmaceutical Inc., Passage Bio, Amicus Therapeutics Inc., PTC Therapeutics, SOM Biotech, ENDECE, StrideBio, Mandos Health, BioMarin Pharmaceutical Inc.

North America was the largest region in the niemann-pick disease (NPD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the niemann-pick disease (npd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the niemann-pick disease (npd) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the niemann-pick disease market by increasing costs associated with imported active pharmaceutical ingredients, biologics, and specialized manufacturing equipment used in orphan drug production. These cost pressures primarily affect drug-based treatment segments and intravenous therapies, with north america and europe experiencing supply chain adjustments due to reliance on global sourcing. While tariffs have led to short-term pricing and procurement challenges, they have also encouraged localized manufacturing, strategic partnerships, and regional clinical research investments, supporting long-term market resilience and supply security.

The niemann-pick disease (npd) market research report is one of a series of new reports that provides niemann-pick disease (npd) market statistics, including niemann-pick disease (npd) industry global market size, regional shares, competitors with a niemann-pick disease (npd) market share, detailed niemann-pick disease (npd) market segments, market trends and opportunities, and any further data you may need to thrive in the niemann-pick disease (npd) industry. This niemann-pick disease (npd) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Niemann-Pick disease (NPD) is a rare inherited lysosomal storage disorder caused by mutations in the SMPD1 (Types A and B) or NPC1/NPC2 (Type C) genes, resulting in excessive lipid accumulation within cells. This buildup leads to progressive damage to the brain, liver, spleen, and other organs. Symptoms vary depending on the type and may include neurodegeneration, hepatosplenomegaly, respiratory complications, and developmental delays.

The primary types of Niemann-Pick disease are Niemann-Pick disease type A, Niemann-Pick disease type B, and Niemann-Pick disease type C. Niemann-Pick disease type A is a rare, severe genetic disorder caused by a deficiency of the enzyme acid sphingomyelinase (ASM), which results in sphingomyelin accumulation in multiple organs. Treatment options include drugs, physical therapy, and other interventions, administered through various routes such as oral, intravenous, and subcutaneous. These therapies are distributed through hospital pharmacies, retail pharmacies, and other channels, and are utilized by end users including hospitals, clinics, and homecare settings.

The niemann-pick disease (NPD) market consists of revenues earned by entities by providing services such as diagnostic testing, genetic counseling, patient support programs, clinical trial management, drug development, and regulatory consulting. The market value includes the value of related goods sold by the service provider or included within the service offering. The niemann-pick disease (NPD) market also includes sales of gene therapy products, enzyme replacement tools, diagnostic kits, biomarker testing tools, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.